BTAI
NASDAQ
$1.14
BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Sector:
Healthcare
Hold
Target: $14 (+1128.07%)
Market Cap
$30M
Beta (5Y)
2.03
Price Chart
Valuation
Market Cap$30M
P/S49.49
P/B27.50
Profitability
Total Revenue (TTM)$680K
Gross Profit (TTM)$247K
EBITDA-$50M
Operating Margin-4963%
EPS-$5.47
Financial Health
Debt-to-Equity-95%
Growth & Risk
FCF 5Y CAGR-5.07%
Beta (5Y)2.03
Sharpe Ratio0.24